Cyclacel raises $8M in private placement of common stock and warrants

Bio Green Med Solution, Inc.

Sold 4,968,945 shares (or pre-funded warrants) plus series A/B warrants at $1.61 per unit; gross proceeds ~$8.0M.
Series A warrants exercisable at $1.36 for 5.5 years; series B warrants for 18 months.
H.C. Wainwright acted as placement agent; fees 7% cash plus 1% management fee and placement agent warrants.
Net proceeds intended for working capital and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Bio Green Med Solution, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $8.0 million (effective 2024-04-30).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: approximately $8.0 million
Effective: 2024-04-30

Exact text from the filing

On April 30, 2024, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 145,000 shares of the Company’s common stock

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-056469

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.